Virtual Library
Start Your Search
S. Apostolaki
Author of
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-083 - Prognostic Significance of CK19mRNA Positive Cells in the Peripheral Blood of Patients with Advanced Non Small Cell Lung Cancer (NSCLC) (ID 760)
09:30 - 09:30 | Author(s): S. Apostolaki
- Abstract
Background:
Circulating Tumor Cells (CTCs) have been shown to be a useful prognostic tool in several cancers. Non-small-cell-lung cancer (NSCLC) lacks validated prognostic biomarkers and, thus, this study aimed to explore the sensitivity and clinical significance of the detection of CK19mRNA (+) CTCs in NSCLC patients.
Methods:
Peripheral blood was obtained from 642 patients with previously untreated stage IIIB/IV NSCLC and from 455 patients after the completion of 1[st] line chemotherapy. RNA extracted from the Calu-3 and ARH-77 cell lines was used as positive and negative controls, respectively. The detection of CK19mRNA-positive cells was performed using an RT-qPCR assay.
Results:
The analytical detection limit of the method was found to correspond to 0.42 Calu-3 cell equivalents/5μg RNA. One hundred and sixty seven (26.0%) patients had detectable CK19mRNA (+) CTCs at baseline; the detection of CK19mRNA (+) CTCs post chemotherapy was associated with significantly decreased PFS and OS (PFS: 2.6 vs 3.8 months, p=0.008; OS: 5.7 vs 10.0 months, p=0.006). Multivariate analysis revealed that gender, performance status and the detection of CK19mRNA (+) CTCs post chemotherapy emerged as independent factors associated with reduced PFS (HR=1.350, p=0.010) and OS (HR=1.608; p=0.001).
Conclusion:
Detection of peripheral blood CK19mRNA (+) CTCs post chemotherapy is an adverse prognostic factor correlated with poor clinical outcome in patients with stage IIIB/IV NSCLC.
